George Sflomos
Overview
Explore the profile of George Sflomos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziegler D, Parashar K, Leal-Esteban L, Lopez-Alcala J, Castro W, Zanou N, et al.
Nat Commun
. 2025 Jan;
16(1):541.
PMID: 39788939
The energetic demands of proliferating cells during tumorigenesis require close coordination between the cell cycle and metabolism. While CDK4 is known for its role in cell proliferation, its metabolic function...
2.
Geukens T, De Schepper M, Van Den Bogaert W, Van Baelen K, Maetens M, Pabba A, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):31.
PMID: 38658604
Research on metastatic cancer has been hampered by limited sample availability. Here we present the breast cancer post-mortem tissue donation program UPTIDER and show how it enabled sampling of a...
3.
Flaherty R, Sflomos G, Brisken C
Endocrinology
. 2024 Mar;
165(5).
PMID: 38551031
Lobular carcinoma represent the most common special histological subtype of breast cancer, with the majority classed as hormone receptor positive. Rates of invasive lobular carcinoma in postmenopausal women have been...
4.
Bacci M, Lorito N, Smiriglia A, Subbiani A, Bonechi F, Comito G, et al.
Sci Transl Med
. 2024 Feb;
16(736):eadf9874.
PMID: 38416843
Targeting aromatase deprives ER breast cancers of estrogens and is an effective therapeutic approach for these tumors. However, drug resistance is an unmet clinical need. Lipidomic analysis of long-term estrogen-deprived...
5.
Sflomos G, Schaumann N, Christgen M, Christgen H, Bartels S, Kreipe H, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444409
Invasive lobular carcinoma (ILC) is a common breast cancer subtype that is often diagnosed at advanced stages and causes significant morbidity. Late-onset secondary tumor recurrence affects up to 30% of...
6.
Aouad P, Zhang Y, De Martino F, Stibolt C, Ali S, Ambrosini G, et al.
Nat Commun
. 2022 Aug;
13(1):4975.
PMID: 36008376
More than 70% of human breast cancers (BCs) are estrogen receptor α-positive (ER). A clinical challenge of ER BC is that they can recur decades after initial treatments. Mechanisms governing...
7.
Scabia V, Ayyanan A, De Martino F, Agnoletto A, Battista L, Laszlo C, et al.
Nat Commun
. 2022 Jun;
13(1):3127.
PMID: 35668111
Estrogen and progesterone receptor (ER, PR) signaling control breast development and impinge on breast carcinogenesis. ER is an established driver of ER + disease but the role of the PR,...
8.
Sflomos G, Schipper K, Koorman T, Fitzpatrick A, Oesterreich S, Lee A, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771558
Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancer (BC) cases and responds well to endocrine treatment when estrogen receptor α-positive (ER) yet differs in many...
9.
Shamseddin M, De Martino F, Constantin C, Scabia V, Lancelot A, Laszlo C, et al.
EMBO Mol Med
. 2021 May;
13(7):e14314.
PMID: 34042278
Hormonal contraception exposes women to synthetic progesterone receptor (PR) agonists, progestins, and transiently increases breast cancer risk. How progesterone and progestins affect the breast epithelium is poorly understood because we...
10.
Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1
Sflomos G, Battista L, Aouad P, De Martino F, Scabia V, Stravodimou A, et al.
EMBO Mol Med
. 2021 Feb;
13(3):e13180.
PMID: 33616307
Invasive lobular carcinoma (ILC) is the most frequent special histological subtype of breast cancer, typically characterized by loss of E-cadherin. It has clinical features distinct from other estrogen receptor-positive (ER...